Debt rising as profit falls
Total debt rose 50.4% while net profit fell 27.4% — worth checking how the balance sheet is being funded.
Importance 76 / 95 · financial health
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Total debt rose 50.4% while net profit fell 27.4% — worth checking how the balance sheet is being funded.
Importance 76 / 95 · financial health
Revenue grew 3.2% but profit declined 27.4%, so the company kept less of each rupee of revenue as profit.
Importance 74 / 95 · growth
EBITDA margin dropped 6.4 percentage points in a single year, from 29.5% to 23.2% — worth investigating.
Importance 70 / 95 · anomaly
Net worth compounded at 18.8% a year over 4 years (₹19,212 → ₹38,231).
Importance 57 / 95 · financial health
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
Peer set used on this page: 12 pharmaceuticals.
Revenue grew 11.8% a year over 4 years, from ₹21,545 cr in FY2022 to ₹33,700 cr in FY2026. Net profit grew 17.5% a year over the same period.
Revenue grew 3.2% but profit declined 27.4%, so the company kept less of each rupee of revenue as profit.
Rule PROFIT_SLOWER_THAN_REVENUE
Over 4 years profit compounded at 17.5% a year while revenue compounded at 11.8% a year — though FY2023 saw a one-off step-change of 107% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Net profit fell 27.4% year on year (FY2025 → FY2026).
Revenue has compounded at 11.8% a year over 4 years (₹21,545 → ₹33,700) — steady rather than rapid.
In Q2 FY27 (Jul–Sep 2026), revenue was ₹8,698 cr (down 1.5% on the same quarter last year) and net profit ₹913 cr (down 31.7%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 net profit was ₹913 cr, down 31.7% from ₹1,337 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 EBITDA margin was 21.7%, down 4.74 percentage points from 26.4% a year earlier.
Rule QTR_MARGIN_CHANGED_YOY
Q2 FY27 net profit declined 31.7% while revenue declined 1.5% vs the same quarter last year — a gap of 30.2 percentage points.
Rule QTR_PROFIT_VS_REVENUE_GROWTH
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 8,381 | +15.8% | 1,404 | +1.7% | 16.8% |
| Q4 FY25 | 8,528 | +19.9% | 1,587 | +21.1% | 18.6% |
| Q1 FY26 | 8,572 | +11.4% | 1,410 | +1.3% | 16.4% |
| Q2 FY26 | 8,828 | +9.8% | 1,337 | −0.4% | 15.1% |
| Q3 FY26 | 8,753 | +4.4% | 1,190 | −15.3% | 13.6% |
| Q4 FY26 | 7,546 | −11.5% | 221 | −86.1% | 2.9% |
| Q1 FY27 | 8,100 | −5.5% | 436 | −69.1% | 5.4% |
| Q2 FY27 | 8,698 | −1.5% | 913 | −31.7% | 10.5% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 23.2% in FY2026, against 19.7% in FY2022. ROE was 11.5% and ROCE 13.9% in FY2026.
ROE declined from 18.4% to 11.5% year on year.
Rule ROE_DETERIORATED_YOY
EBITDA margin has ranged from 19.7% to 31.5% over 4 years and sits at 23.2% now.
Debt-to-equity was 0.16x in FY2026, against 0.17x in FY2022; interest coverage 15.39x. Operating cash flow was 1.36x net profit.
Total debt rose 50.4% while net profit fell 27.4% — worth checking how the balance sheet is being funded.
Rule DEBT_UP_EARNINGS_DOWN
Net worth compounded at 18.8% a year over 4 years (₹19,212 → ₹38,231).
Free cash flow has been positive in 5 of the last 5 years.
Within its 12-company Pharmaceuticals peer group, it ranks 10 of 12 on return on equity and 10 of 12 on EBITDA margin. Its P/E of 42.1 compares with a peer median of 45.3.
Ranked against 12 pharmaceuticals (FY2026, consolidated).
DRREDDY · 11th of 12 · set median 14.8%
DRREDDY · 10th of 12 · set median 28.7%
DRREDDY · 10th of 12 · set median 14.4%
DRREDDY · 6th of 12 · set median 45.3×
Trades at 3.04× book — 36% below the pharmaceuticals median of 4.74×.
Rule PB_BELOW_PEERS
On the trailing twelve months. Last full year: P/E 27.9× · P/S 3.3× · ROE 11.5%. TTM and full-year profit and EBITDA differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.
The share price is up 11.4% over 1 year, up 23.1% over 3 years (7.2% a year) and up 48.8% over 5 years (8.3% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 0.5% below its 52-week high.
Over 4 years profit compounded at 17.5% a year while the stock returned 7.2% a year — but FY2022 profit (₹2,183) was well below the through-cycle level (~₹4,507), so this rate is inflated by the recovery from a low base.
Rule STOCK_LAGGED_EARNINGS · recovery
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 21,545 | 24,670 | 28,011 | 32,644 | 33,700 |
| Total income | 22,030 | 25,725 | 28,905 | 33,741 | 35,059 |
| EBITDA | 4,252 | 7,405 | 8,827 | 9,644 | 7,812 |
| Profit before tax | 2,991 | 6,012 | 7,186 | 7,658 | 5,379 |
| Net profit | 2,183 | 4,507 | 5,578 | 5,725 | 4,158 |
| EPS (₹) | 131.6 | 271.5 | 335.2 | 67.9 | 50.4 |
| Net worth | 19,212 | 23,286 | 28,255 | 33,927 | 38,231 |
| Total debt | 3,283 | 1,347 | 1,652 | 4,185 | 6,294 |
| Operating cash flow | 2,811 | 5,887 | 4,543 | 4,643 | 5,674 |
| Free cash flow | 1,382 | 4,763 | 3,009 | 1,944 | 3,374 |
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth YoY | — | 14.5 | 13.5 | 16.5 | 3.2 |
| Profit growth YoY | — | 106.5 | 23.8 | 2.6 | -27.4 |
| Profitability | |||||
| EBITDA margin % | 19.7 | 30.0 | 31.5 | 29.5 | 23.2 |
| Net margin % | 9.9 | 17.5 | 19.3 | 17.0 | 11.9 |
| Return on equity % | 11.4 | 21.2 | 21.6 | 18.4 | 11.5 |
| Return on capital % | 13.7 | 26.1 | 27.0 | 23.3 | 13.9 |
| Leverage & cash | |||||
| Debt to equity | 0.17 | 0.06 | 0.06 | 0.12 | 0.16 |
| Cash flow ÷ profit | 1.29 | 1.31 | 0.81 | 0.81 | 1.36 |
| Current ratio | 1.85 | 2.41 | 2.59 | 1.92 | 1.80 |